Health Care & Life Sciences » Biotechnology | Avax Technologies Inc.

Avax Technologies Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Net Income before Extraordinaries
3,286.10
3,457.90
3,703.80
5,355.50
6,413.60
Depreciation, Depletion & Amortization
414.30
395.10
315.00
290.40
301.00
Other Funds
925.00
-
-
-
-
Funds from Operations
2,838.40
2,950.10
3,388.70
4,916.50
5,913.50
Changes in Working Capital
858.50
372.00
321.70
822.70
1,181.60
Net Operating Cash Flow
3,696.90
2,578.10
3,710.40
4,093.80
4,731.90
Capital Expenditures
6.00
219.20
292.00
40.30
127.40
Sale of Fixed Assets & Businesses
5.60
-
-
-
-
Purchase/Sale of Investments
84.70
262.70
-
-
-
Net Investing Cash Flow
84.30
43.60
292.00
40.30
127.40
Net Financing Cash Flow
925.00
2,941.70
7,986.50
-
9,318.40
Net Change in Cash
2,714.40
434.80
4,012.40
4,088.60
4,418.60
Free Cash Flow
3,703.00
2,797.30
4,002.40
4,134.20
4,859.30
Change in Capital Stock
-
2,941.70
7,986.50
-
9,318.40
Exchange Rate Effect
26.80
27.60
28.30
45.60
40.40
Miscellaneous Funds
0.00
0.00
0.00
0.00
0.00

About Avax Technologies

View Profile
Address
2000 Hamilton Street
Philadelphia Pennsylvania 19130
United States
Employees -
Website http://www.avax-tech.com
Updated 07/08/2019
AVAX Technologies, Inc. operates as bio-technology company, which engages in the provision of development and commercialization of vaccine therapies and technologies for the treatment of cancer. It offers biological manufacturing services to biotechnology and pharmaceutical companies. The company was founded by Kenneth E.